Physician profile
Cherian Abraham
NPI 1134188311
$9,012.31
in general payments reported to CMS, 2019-2025
38 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $448 · 2021: $657 · 2022: $1,225 · 2023: $1,711 · 2024: $1,922 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,816 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,816.43 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,803.87 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,215.33 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $939.14 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $927.63 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $586.54 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $310.28 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $196.01 | 2020-2024 | Dificid |
| Lilly USA, LLC | $194.98 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $158.94 | 2022-2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $138.10 | 2025 | Austedo Xr |
| Qol Medical, LLC | $134.12 | 2019-2024 | Sucraid, Sucraid |
| Pfizer INC. | $133.25 | 2024-2025 | |
| Allergan, INC. | $116.56 | 2019 | |
| Celltrion USA INC. | $114.02 | 2023-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $97.22 | 2022-2025 | Ibsrela |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $92.98 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $78.28 | 2022-2023 | |
| Madrigal Pharmaceuticals | $74.87 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $69.55 | 2023 | Rebyota, Clenpiq |
| Intercept Pharmaceuticals, INC. | $67.46 | 2019-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $65.36 | 2024 | |
| Redhill Biopharma INC. | $61.15 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $60.06 | 2020-2024 | |
| Evoke Pharma, INC. | $53.76 | 2022-2025 | |
| Daiichi Sankyo INC. | $40.04 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $34.69 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $30.52 | 2024 | Terlivaz |
| Shionogi INC | $29.73 | 2019 | |
| Astellas Pharma US INC | $28.61 | 2025 | Vyloy |
| Boston Scientific Corporation | $25.43 | 2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $22.44 | 2023 | Zeposia |
| Novo Nordisk INC | $21.96 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $20.93 | 2025 | Iqirvo |
| Vivus LLC | $19.09 | 2025 | Pancreaze |
| Ethicon US, LLC | $18.57 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.13 | 2019 | |
| Sandoz INC. | $13.71 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,172.63 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherian Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.